Research Perspectives:

Advances in meningioma genomics, proteomics, and epigenetics: insights into biomarker identification and targeted therapies

Ahmad A. Nazem, Jacob Ruzevick and Manuel J. Ferreira Jr _

PDF  |  Full Text  |  How to cite

Oncotarget. 2020; 11:4544-4553. https://doi.org/10.18632/oncotarget.27841

Metrics: PDF 1097 views  |   Full Text 1917 views  |   ?  


Ahmad A. Nazem1,*, Jacob Ruzevick1,* and Manuel J. Ferreira Jr1

1 Department of Neurosurgery, University of Washington School of Medicine, University of Washington Medical Center, Seattle, WA, 98195, USA

* These authors contributed equally to this work

Correspondence to:

Manuel J. Ferreira Jr,email: [email protected]

Keywords: meningioma; skull base; NGS; sequencing; biomarker

Received: October 21, 2020     Accepted: November 03, 2020     Published: December 08, 2020

Copyright: © 2020 Nazem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Meningiomas are a heterogeneous group of tumors, defined histo-pathologically by World Health Organization (WHO) grading. The WHO grade of meningiomas does not always correlate with clinical aggressiveness. Despite maximal surgical resection and adjuvant radiation, a subset of tumors are clinically aggressive; displaying early recurrence and invasion. Current methods for identifying aggressive meningiomas solely focus on genomics, proteomics, or epigenetics and not a combination of all for developing a real-time clinical biomarker. Improved methods for the identification of these outlying tumors can facilitate better classification and potentially adjuvant treatment planning. Understanding the pathways of oncogenesis using multiple markers driving aggressive meningiomas can provide a foundation for targeted therapies, which currently do not exist.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27841